Last reviewed · How we verify
NCT05406635: HER2BIC
Imaging Versus Cardiac Biomarker Monitored HER2 Directed Therapy in Patients With Breast Cancer
NA trial testing Biomarkers: Troponins and natriuretic peptides in Cardiotoxicity in 220 participants. Currently enrolling.
1 February 2026
Quick facts
| Lead sponsor | Odense University Hospital |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 220 |
| Start date | 1 October 2021 |
| Primary completion | 1 February 2026 |
| Estimated completion | 1 September 2027 |
| Sites | 4 locations across Denmark |
Drugs / interventions tested
- Biomarkers: Troponins and natriuretic peptides
Conditions studied
- Cardiotoxicity — all drugs for Cardiotoxicity →
- HER2-positive Breast Cancer — all drugs for HER2-positive Breast Cancer →
Sponsor
Odense University Hospital
Who can join
Adults 18 to 90, female only, with Cardiotoxicity or HER2-positive Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Due to a risk of heart failure during HER2 directed therapy in breast cancer, treatment is monitored with imaging of myocardial function, which is resource demanding for both patients and the health care system. The purpose of this study is to evaluate, if biomarkers can replace imaging based examinations of myocardial function during HER2 directed therapy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05406635
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cardiotoxicity
Currently open trials in the same condition.
- NCT07442578 — Impact of Exercise Intensity on Cardiac Health in Young Adult Survivors of Childhood Cancer: The PULSE Trial · NA · active not recruiting
- NCT06778122 — In-Bedroom Renewed Air as Anti-inflammatory Adjuvant Therapy in Cancer Survivors · NA · recruiting
- NCT07382141 — Early Identification of Cardivascular Damage Induced by Chemotherapy and Antineoplastic Treatments in Pediatric Age · NA · recruiting
- NCT06595147 — Breast cancEr, FITness and ExeRcise for Heart Health: The BE-FITTER Study · NA · recruiting
- NCT06270667 — Effects of Exercise Training in Survivors of Lymphoma · NA · recruiting
Other Odense University Hospital trials
Trials by the same sponsor.
- NCT07163091 — Bracing After Ankle Fracture · NA · not yet recruiting
- NCT07521696 — Physical Recovery During Bracing After Ankle Fracture (Re-BAF) · NA · not yet recruiting
- NCT07466212 — QoLIDia: Quality of Life in Cancer Patients With Diabetes During Immunotherapy · not yet recruiting
- NCT07191379 — Self-administered Subcutaneous Daratumumab in Patients With Multiple Myeloma · Phase 4 · not yet recruiting
- NCT07170085 — Positioning of Children With Acute Respiratory Insufficiency · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05406635 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Odense University Hospital
- Last refreshed: 8 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05406635.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing